In the transaction Alma STA assisted the European Investment Fund, McDermott Will & Emery assisted Claris Venture SGR while Legance acted for CDP Venture Capital SGR.
Claris Venture SGR S.p.A. closes the final round of subscriptions for the Claris I Biotech fund and the first round for the related Claris I Biotech Parallel Fund, closed-end funds focused on early-stage investments in high-potential biopharmaceutical companies born from the Italian R&D ecosystem.
The new subscriptions bring the total commitment of the fund – together with the commitment collected on the parallel fund – to an amount of approximately Euro 85 million.
CDP Venture Capital SGR invested in the Claris I Biotech and Claris I Biotech Parallel Funds on behalf, respectively, of its managed funds Fondo di Fondi VenturItaly and MiSE Co-investment Fund.
The fund also closes thanks to the support of the European Investment Fund (EIF), which contributed with Euro 40 million. The investment is supported by the European Commission’s InnovFin Equity program, funded under the Horizon 2020 program, and by the European Guarantee Fund (EGF), as well as a contribution through the Alpine Growth Investment Platform (AlpGIP).
Alma STA assisted the European Investment Fund with a team led by managing partner Alessandro Corno (Picture) alongside senior associate Virgilio Sollima.
McDermott Will & Emery assisted Claris Venture SGR and the funds management team with a led by partner Emidio Cacciapuoti assisted by senior associate Giorgio Bobba.
Legance – Avvocati Associati advised CDP Venture Capital SGR with a team led by senior partner Enzo Schiavello alongside associate Valentina Santoni.
Involved fees earner: Alessandro Corno – Alma STA; Virgilio Sollima – Alma STA; Valentina Santoni – Legance; Enzo Schiavello – Legance; Giorgio Bobba – McDermott Will & Emery; Emidio Cacciapuoti – McDermott Will & Emery;